ERBB2 and non-small cell lung carcinoma: In addition, T‐DXd was also evaluated in pretreated, HER2‐expressing, or HER2‐mutant advanced solid tumors (including non‐small cell lung cancer [NSCLC], colorectal cancer, and other solid cancers) in the phase 1 NCT02564900 trial.